NCT06509945View on ClinicalTrials.gov

Allo-PBSCT as the First-line Treatment for Patients With the High-risk PTCL

NARecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

July 15, 2024

Primary Completion Date

July 15, 2026

Study Completion Date

July 15, 2026

Conditions
Peripheral T Cell Lymphoma
Interventions
OTHER

allogeneic peripheral blood stem cell transplantation

Patients achieved response to treatment will receive allogeneic peripheral blood stem cell transplantation.

Trial Locations (1)

200080

RECRUITING

Shanghai General Hospital, Shanghai

All Listed Sponsors
lead

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

OTHER